Fragment-Based Drug Discovery Using Rational Design (original) (raw)

References

• Berdini V, O'Reilly M, Congreve MS, Tickle IJ (2007) Fragment-based screening by X-ray crystallography. Jhoti H, Leach AR (eds) Structure-based drug discovery. Springer, Berlin Heidelberg New York, pp 99–123
  Google Scholar
• Beteva A, Cipriani F, Cusack S, Delageniere S, Gabadinho J, Gordon EJ, Guijarro M, Hall DR, Larsen S, Launer L, Lavault CB, Leonard GA, Mairs T, McCarthy A, McCarthy J, Meyer J, Mitchell E, Monaco S, Nurizzo D, Pernot P, Pieritz R, Ravelli RG, Rey V, Shepard W, Spruce D, Stuart DI, Svensson O, Theveneau P, Thibault X, Turkenburg J, Walsh M, McSweeney SM (2006) High-throughput sample handling and data collection at synchrotrons: embedding the ESRF into the high-throughput gene-to-structure pipeline. Acta Cryst D Biol Crystallogr 62:1162–1169
  Article CAS Google Scholar
• Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Disc 1:45–54
  Article CAS Google Scholar
• Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY (2005) A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201–207
  Article PubMed CAS Google Scholar
• Carr R, Jhoti H (2002) Structure-based screening of low-affinity compounds. Drug Discov Today 7:522–527
  Article PubMed CAS Google Scholar
• Congreve M, Carr R, Murray C, Jhoti H (2003) A 'rule of three'™ for fragment-based lead discovery? Drug Discov Today 8:876–877
  Article PubMed Google Scholar
• Erlanson DA, McDowell RS, O'Brien T (2004a) Fragment-based drug discovery. J Med Chem 47:3463–3482
  Article PubMed CAS Google Scholar
• Evrard GX, Langer GG, Perrakis A, Lamzin VS (2007) Assessment of automatic ligand building in ARP/wARP. Acta Cryst D Biol Crystallogr 63:108–117
  Article Google Scholar
• Fischer PM, Lane DP (2000) Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr Med Chem 7:1213–1245.
  Google Scholar
• Forstner M, Leder L, Mayr LM (2007) Optimization of protein expression systems for modern drug discovery. Expert Rev Proteomics 4:67–78
  Article PubMed CAS Google Scholar
• Gill AL (2004) New lead generation strategies for protein kinase inhibitors – fragment-based screening approaches, Mini-reviews Med Chem 4:301–311
  CAS Google Scholar
• Gill A, Frederickson M, Cleasby A, Woodhead SJ, Carr MG, Woodhead AJ, Walker MT, Congreve MS, Devine LA, Tisi D, Magor LCA, Davis DJ, Curry J, Anthony R, Padova A, Murray CW, Carr RAE, Jhoti H (2005) Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J Med Chem 48:414–426
  Article PubMed CAS Google Scholar
• Hajduk PJ, Mack JC, Olejniczak ET, Park C, Dandliker PJ, Beutel BA (2004) SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. J Am Chem Soc 126:2390–2398
  Article PubMed CAS Google Scholar
• Hajduk PJ (2006) Fragment-based drug design: how big is too big? J Med Chem 49:6972–6976
  Article PubMed CAS Google Scholar
• Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211–219
  Article PubMed CAS Google Scholar
• Hann MM, Leach AR, Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comp Sci 41:856–864
  Article CAS Google Scholar
• Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H (2005) Fragment-based lead discovery using X-ray crystallography. J Med Chem 48:403–413
  Article PubMed CAS Google Scholar
• Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 9:430–431
  Article PubMed Google Scholar
• Jahnke W, Erlanson DA (2006) Fragment-based approaches in drug discovery. Wiley-VCH
  Google Scholar
• Jhoti H (2003) High-throughput X-ray techniques and drug discovery. In: Waldman H, Koppitz M (eds) Small molecule-protein interactions. (Ernst-Schering Research Foundation) Springer, Berlin Heidelberg New York, pp 43–58
  Google Scholar
• Jhoti H, Leach AR (2007) Structure-based drug discovery. Springer, Berlin Heidelberg New York
  Google Scholar
• Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) The maximal affinity of ligands. Proc Natl Acad Sci USA 96:9997–10002
  Article PubMed CAS Google Scholar
• Lepre CA, Moore JM (2007) Fragment-based NMR Screening in lead discovery. In: Jhoti H, Leach AR (eds) Structure-based drug discovery. Springer, Berlin Heidelberg New York, pp 73–98
  Google Scholar
• Mayer M, Meyer B (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123:6108–6117
  Article PubMed CAS Google Scholar
• McCoy MA, Senior MM, Wyss DF (2005) Screening of protein kinases by ATP-STD NMR spectroscopy. J Am Chem Soc 127:7978–7979
  Article PubMed CAS Google Scholar
• Mooij WT, Hartshorn MJ, Tickle IJ, Sharff AJ, Verdonk ML, Jhoti H (2006) Automated protein-ligand crystallography for structure-based drug design. Chem Med Chem 1:827–838
  PubMed CAS Google Scholar
• Muchmore SW, Olson J, Jones R, Pan J, Blum M, Greer J, Merrick SM, Magdalinos P, Nienaber VL (2000) Automated crystal mounting and data collection for protein crystallography. Structure 8:R243–R246
  Article PubMed CAS Google Scholar
• Murray CW, Verdonk ML (2002) The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J Comp-Aided Mol Design 16:741–753
  Article CAS Google Scholar
• Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18:1105–1108
  Article PubMed CAS Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681
  Article PubMed CAS Google Scholar
• Oldfield TJ (2001) X-LIGAND: an application for the automated addition of flexible ligands into electron density. Acta Cryst D Biol Crystallogr 57:696–705
  Article CAS Google Scholar
• Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3:660–672
  Article PubMed CAS Google Scholar
• Sanchez-Pedregal VM, Reese M, Meiler J, Blommers MJ, Griesinger C, Carlomagno T (2005) The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. Angew Chem Int Ed Engl 44:4172–4175
  Article PubMed CAS Google Scholar
• Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531–1534
  Article PubMed CAS Google Scholar
• Stevens RC (2000) High-throughput protein crystallization, Curr Opin Struct Biol 10:558–563
  CAS Google Scholar
• Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609–623
  Article PubMed CAS Google Scholar
• Verlinde CLMJ, Kim H, Bernstein BE, Mande SC, Hol WGJ (1997) in Structure-based drug design. Edited by Veerapandian P. Marcel Dekker, New York, pp. 365–394
  Google Scholar

Download references